Arctigenin derivative (ARC-18) improved mitochondrial dysfunction and ameliorated frataxin deficiency symptoms via PGC-1α signaling

Gong Q, Han X, Liu T, Xiong B, Zhang B, Xie Y, Wan H, Ali T, Yang X, Li S. Arctigenin derivative (ARC-18) improved mitochondrial dysfunction and ameliorated frataxin deficiency symptoms via PGC-1α signaling. Genes Dis. 2025 Sep 1;13(4):101838. doi: 10.1016/j.gendis.2025.101838. PMID: 41884717; PMCID: PMC13011025.

Notably, co-treatment with the PGC-1α inhibitor SR-18292 abolished ARC-18 effects, confirming its dependence on PGC-1α activation to rescue mitochondrial deficits in FXN-deficient cells.

Arctigenin derivative (ARC-18) improved mitochondrial dysfunction and ameliorated frataxin deficiency symptoms via PGC-1α signaling